Key result
Activated protein C resistance linked to ~3-fold higher VTE risk under age 70, but not over 70.
Why the study?
Previous studies on APC resistance as a risk factor for venous thromboembolism mostly analyzed patients under 70 years, leaving uncertainty about its role in older patients.
Is activated protein C (APC) resistance a risk factor for venous thromboembolism in patients over 70 years of age?
Case-Control (n=1,027)
Is activated protein C (APC) resistance a risk factor for venous thromboembolism in patients over 70 years of age?
Odds Ratio: 0.8 (95% CI 0.4–1.7)
Activated protein C (APC) resistance related to factor V Leiden does not appear to be a significant risk factor for venous thromboembolism in patients over 70 years of age.
No takes yet. Share an insight, caveat, or question.
APC resistance associated with VTE across ages; extends younger-cohort data but leaves open testing utility.
Oger et al. (2002) conducted a case-control in Venous thromboembolism (n=1,027). Activated protein C (APC) resistance vs. No APC resistance was evaluated on Venous thromboembolism in patients over 70 years (OR 0.8, 95% CI 0.4 to 1.7). Activated protein C resistance increased VTE risk in patients under 70 years (OR 3.2; 95% CI 1.7-6.0) but was not a significant risk factor in patients over 70 years (OR 0.8; 95% CI 0.4-1.7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: